<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39420230</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1939-0041</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Season>Sep-Oct</Season></PubDate></JournalIssue><Title>Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology</Title><ISOAbbreviation>Wiley Interdiscip Rev Nanomed Nanobiotechnol</ISOAbbreviation></Journal><ArticleTitle>Nanomedicine Therapies for Pediatric Diseases.</ArticleTitle><Pagination><StartPage>e1996</StartPage><MedlinePgn>e1996</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/wnan.1996</ELocationID><Abstract><AbstractText>In 2020, the top 10 causes of death among children and adolescents between the ages of 1 and 19 years old included cancer, congenital anomalies, heart disease, and chronic respiratory disease; all these conditions are potentially treatable with medical intervention. However, children exhibit specific physiological and developmental characteristics that can significantly impact drug pharmacokinetics, pharmacodynamics, and safety profile. These factors illustrate the importance of a heightened focus on pediatric drug development. Traditional drugs lack proper circulation, permeability, targeting, accumulation, and release, and they often require dose adjustments or modifications, which can result in suboptimal therapeutic outcomes and increased risks of adverse effects in pediatric patients. Nanomedicines have emerged as efficient drug delivery systems because of their unique properties, which can improve the solubility and stability of drugs by encapsulating them in different forms of nanoparticles. This review discusses the challenges of pediatric therapy, and the current state of nanomedicines for pediatric diseases in terms of Food and Drug Administration-approved nanomedicines, the types of diseases treated or diagnosed, and preclinical studies that have the potential to be translated to the clinic. In summary, nanomedicine holds significant potential for addressing the unique and pressing challenges associated with diagnosing and treating pediatric diseases.</AbstractText><CopyrightInformation>© 2024 The Author(s). WIREs Nanomedicine and Nanobiotechnology published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Shicheng</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8039-5668</Identifier><AffiliationInfo><Affiliation>Department of Chemical Engineering, Northeastern University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>Kushi</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-8865-5359</Identifier><AffiliationInfo><Affiliation>Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jurczyszak</LastName><ForeName>Jillian</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5223-0161</Identifier><AffiliationInfo><Affiliation>Cancer Nanomedicine Co-Ops for Undergraduate Research Experience (CaNCURE), Northeastern University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Needa</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-3355-1354</Identifier><AffiliationInfo><Affiliation>Department of Physics, Northeastern University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sridhar</LastName><ForeName>Srinivas</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1605-0734</Identifier><AffiliationInfo><Affiliation>Department of Chemical Engineering, Northeastern University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physics, Northeastern University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Bioengineering, Northeastern University, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R25 CA174650</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R25CA174650</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Wiley Interdiscip Rev Nanomed Nanobiotechnol</MedlineTA><NlmUniqueID>101508311</NlmUniqueID><ISSNLinking>1939-0041</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050997" MajorTopicYN="Y">Nanomedicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010372" MajorTopicYN="N">Pediatrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19 vaccine</Keyword><Keyword MajorTopicYN="N">FDA approval</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">nanomedicine</Keyword><Keyword MajorTopicYN="N">pediatric disease</Keyword><Keyword MajorTopicYN="N">preclinical study</Keyword></KeywordList><CoiStatement>Conflict of Interest. No potential conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>18</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>23</Hour><Minute>45</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39420230</ArticleId><ArticleId IdType="mid">NIHMS2023947</ArticleId><ArticleId IdType="pmc">PMC11493394</ArticleId><ArticleId IdType="doi">10.1002/wnan.1996</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abballe L, Spinello Z, Antonacci C, Coppola L, Miele E, Catanzaro G, Miele E. (2023). Nanoparticles for Drug and Gene Delivery in Pediatric Brain Tumors’ Cancer Stem Cells: Current Knowledge and Future Perspectives. Pharmaceutics. 15(2):505. 10.3390/pharmaceutics15020505</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics15020505</ArticleId><ArticleId IdType="pmc">PMC9962005</ArticleId><ArticleId IdType="pubmed">36839827</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdellatif AAH, &amp; Alsowinea AF (2021). Approved and marketed nanoparticles for disease targeting and applications in COVID-19. Nanotechnology Reviews, 10(1), 1941–1977. 10.1515/ntrev-2021-0115</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/ntrev-2021-0115</ArticleId></ArticleIdList></Reference><Reference><Citation>Adepu S, &amp; Ramakrishna S (2021). Controlled Drug Delivery Systems: Current Status and Future Directions. Molecules, 26(19). 10.3390/molecules26195905</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26195905</ArticleId><ArticleId IdType="pmc">PMC8512302</ArticleId><ArticleId IdType="pubmed">34641447</ArticleId></ArticleIdList></Reference><Reference><Citation>Adhikari C (2021). Polymer nanoparticles-preparations, applications and future insights: a concise review. Polymer-Plastics Technology and Materials, 60(18), 1996–2024. 10.1080/25740881.2021.1939715</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/25740881.2021.1939715</ArticleId></ArticleIdList></Reference><Reference><Citation>Afzal E, Zakeri S, Keyhanvar P, Bagheri M, Mahjoubi P, Asadian M, Omoomi N, Dehqanian M, Ghalandarlaki N, Darvishmohammadi T, Farjadian F, Golvajoee MS, Afzal S, Ghaffari M, Cohan RA, Gravand A, &amp; Ardestani MS (2013). Nanolipodendrosome-loaded glatiramer acetate and myogenic differentiation 1 as augmentation therapeutic strategy approaches in muscular dystrophy. Int J Nanomedicine, 8, 2943–2960. 10.2147/ijn.S43219</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/ijn.S43219</ArticleId><ArticleId IdType="pmc">PMC3743640</ArticleId><ArticleId IdType="pubmed">23966782</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfayez M, Kantarjian H, Kadia T, Ravandi-Kashani F, &amp; Daver N (2020). CPX-351 (vyxeos) in AML. Leuk Lymphoma, 61(2), 288–297. 10.1080/10428194.2019.1660970</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10428194.2019.1660970</ArticleId><ArticleId IdType="pubmed">31547736</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson BJ, &amp; Holford NH (2013). Understanding dosing: children are small adults, neonates are immature children. Arch Dis Child, 98(9), 737–744. 10.1136/archdischild-2013-303720</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/archdischild-2013-303720</ArticleId><ArticleId IdType="pubmed">23832061</ArticleId></ArticleIdList></Reference><Reference><Citation>Andra VVSNL, Pammi SVN, Bhatraju LVKP, &amp; Ruddaraju LK (2022). A Comprehensive Review on Novel Liposomal Methodologies, Commercial Formulations, Clinical Trials and Patents. BioNanoScience, 12(1), 274–291. 10.1007/s12668-022-00941-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12668-022-00941-x</ArticleId><ArticleId IdType="pmc">PMC8790012</ArticleId><ArticleId IdType="pubmed">35096502</ArticleId></ArticleIdList></Reference><Reference><Citation>Auerbach M, &amp; Rodgers GM (2007). Intravenous iron. N Engl J Med, 357(1), 93–94. 10.1056/NEJMc070203</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc070203</ArticleId><ArticleId IdType="pubmed">17611217</ArticleId></ArticleIdList></Reference><Reference><Citation>Avramis VI, &amp; Panosyan EH (2005). Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet, 44(4), 367–393. 10.2165/00003088-200544040-00003</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003088-200544040-00003</ArticleId><ArticleId IdType="pubmed">15828851</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayuso M, Buyssens L, Stroe M, Valenzuela A, Allegaert K, Smits A, Annaert P, Mulder A, Carpentier S, Van Ginneken C, &amp; Van Cruchten S (2020). The Neonatal and Juvenile Pig in Pediatric Drug Discovery and Development. Pharmaceutics, 13(1), 44. 10.3390/pharmaceutics13010044</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics13010044</ArticleId><ArticleId IdType="pmc">PMC7823749</ArticleId><ArticleId IdType="pubmed">33396805</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz S (2014). Treatment of Hepatitis C Virus Infection in Children Less than 12 Years of Age in Developing Countries. J Clin Transl Hepatol, 2(4), 247–252. 10.14218/jcth.2014.00034</Citation><ArticleIdList><ArticleId IdType="doi">10.14218/jcth.2014.00034</ArticleId><ArticleId IdType="pmc">PMC4521235</ArticleId><ArticleId IdType="pubmed">26356647</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldwin P, Likhotvorik R, Baig N, Cropper J, Carlson R, Kurmasheva R, &amp; Sridhar S (2019). Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma. Front Oncol, 9, 1416–1416. 10.3389/fonc.2019.01416</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2019.01416</ArticleId><ArticleId IdType="pmc">PMC6928193</ArticleId><ArticleId IdType="pubmed">31921673</ArticleId></ArticleIdList></Reference><Reference><Citation>Batchelor HK, &amp; Marriott JF (2015). Paediatric pharmacokinetics: key considerations. Br J Clin Pharmacol, 79(3), 395–404. 10.1111/bcp.12267</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.12267</ArticleId><ArticleId IdType="pmc">PMC4345950</ArticleId><ArticleId IdType="pubmed">25855821</ArticleId></ArticleIdList></Reference><Reference><Citation>Beleck A, &amp; Nachman S (2021). Understanding Pediatric Drug Lag Time: Review of Selected Drug Package Inserts. J Pediatric Infect Dis Soc, 10(4), 509–513. 10.1093/jpids/piaa136</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/piaa136</ArticleId><ArticleId IdType="pubmed">33289506</ArticleId></ArticleIdList></Reference><Reference><Citation>Belz JE, Kumar R, Baldwin P, Ojo NC, Leal AS, Royce DB, Zhang D, van de Ven AL, Liby KT, &amp; Sridhar S (2017). Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer. Theranostics, 7(17), 4340–4349. 10.7150/thno.18563</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.18563</ArticleId><ArticleId IdType="pmc">PMC5695017</ArticleId><ArticleId IdType="pubmed">29158830</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernhardt MB, Lindsay H, Allen-Rhoades W, &amp; Foster JH (2021). The Best Pharmaceuticals for Children Act and Pediatric Research Equity Act reach the age of majority—An oncology perspective. Pediatr Blood Cancer, 68(3), e28871. 10.1002/pbc.28871</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pbc.28871</ArticleId><ArticleId IdType="pubmed">33381908</ArticleId></ArticleIdList></Reference><Reference><Citation>Burckart GJ, &amp; Kim C (2020). The Revolution in Pediatric Drug Development and Drug Use: Therapeutic Orphans No More. J Pediatr Pharmacol Ther, 25(7), 565–573. 10.5863/1551-6776-25.7.565</Citation><ArticleIdList><ArticleId IdType="doi">10.5863/1551-6776-25.7.565</ArticleId><ArticleId IdType="pmc">PMC7541025</ArticleId><ArticleId IdType="pubmed">33041711</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabral H, Li J, Miyata K, &amp; Kataoka K (2024). Controlling the biodistribution and clearance of nanomedicines. Nat Rev Bioeng 2, 214–232. 10.1038/s44222-023-00138-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s44222-023-00138-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao W, Kim JH, Chirkova T, Reber AJ, Biber R, Shay DK, &amp; Sambhara S (2011). Improving immunogenicity and effectiveness of influenza vaccine in older adults. Expert Rev Vaccines, 10(11), 1529–1537. 10.1586/erv.11.137</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.11.137</ArticleId><ArticleId IdType="pubmed">22043953</ArticleId></ArticleIdList></Reference><Reference><Citation>Cella M, Knibbe C, Danhof M, &amp; Della Pasqua O (2010). What is the right dose for children? British Journal of Clinical Pharmacology, 70(4), 597–603. 10.1111/j.1365-2125.2009.03591.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.2009.03591.x</ArticleId><ArticleId IdType="pmc">PMC2950994</ArticleId><ArticleId IdType="pubmed">21087295</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CY, Tran DM, Cavedon A, Cai X, Rajendran R, Lyle MJ, Martini PGV, &amp; Miao CH (2020). Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles. Mol Ther Nucleic Acids, 20, 534–544. 10.1016/j.omtn.2020.03.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2020.03.015</ArticleId><ArticleId IdType="pmc">PMC7178004</ArticleId><ArticleId IdType="pubmed">32330871</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng F, Wang Y, Bai Y, Liang Z, Mao Q, Liu D, Wu X, &amp; Xu M (2023). Research Advances on the Stability of mRNA Vaccines. Viruses, 15(3), 668. 10.3390/v15030668</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15030668</ArticleId><ArticleId IdType="pmc">PMC10051489</ArticleId><ArticleId IdType="pubmed">36992377</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciccocioppo R, Kruzliak P, Cangemi GC, Pohanka M, Betti E, Lauret E, &amp; Rodrigo L (2015). The Spectrum of Differences between Childhood and Adulthood Celiac Disease. Nutrients, 7(10), 8733–8751. 10.3390/nu7105426</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu7105426</ArticleId><ArticleId IdType="pmc">PMC4632446</ArticleId><ArticleId IdType="pubmed">26506381</ArticleId></ArticleIdList></Reference><Reference><Citation>Corma A, Botella P, &amp; Rivero-Buceta E (2022). Silica-Based Stimuli-Responsive Systems for Antitumor Drug Delivery and Controlled Release. Pharmaceutics, 14(1). 10.3390/pharmaceutics14010110</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14010110</ArticleId><ArticleId IdType="pmc">PMC8779356</ArticleId><ArticleId IdType="pubmed">35057006</ArticleId></ArticleIdList></Reference><Reference><Citation>de Almeida Campos L, Fin MT, Santos KS, de Lima Gualque MW, Freire Cabral AKL, Khalil NM, Fusco-Almeida AM, Mainardes RM, &amp; Mendes-Giannini MJS (2023). Nanotechnology-Based Approaches for Voriconazole Delivery Applied to Invasive Fungal Infections. Pharmaceutics, 15(1). 10.3390/pharmaceutics15010266</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics15010266</ArticleId><ArticleId IdType="pmc">PMC9863752</ArticleId><ArticleId IdType="pubmed">36678893</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y, Shen L, Yang Y, &amp; Shen J (2021). Development of nanoparticle-based orodispersible palatable pediatric formulations. Int J Pharm, 596, 120206. 10.1016/j.ijpharm.2021.120206</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2021.120206</ArticleId><ArticleId IdType="pmc">PMC7980133</ArticleId><ArticleId IdType="pubmed">33493595</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingues C; Jarak I; Veiga F; Dourado M; Figueiras A (2023). Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies. Pharmaceutics, 15, 2431. 10.3390/pharmaceutics15102431</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics15102431</ArticleId><ArticleId IdType="pmc">PMC10610377</ArticleId><ArticleId IdType="pubmed">37896191</ArticleId></ArticleIdList></Reference><Reference><Citation>Drugs.com. (2021, May
22, 2023). FDA Professional Drug Information. Engerix B Prescribing Information. Retrieved
Jun 18, 2023
from https://www.drugs.com/pro/engerix-b.html.</Citation></Reference><Reference><Citation>Durbin Pharamceuticals. Hepatate kit for the preparation of technitium. DurbinGlobal.com.
https://www.durbinglobal.com/assets/images/products/pdf/Hepatate_spc.pdf</Citation></Reference><Reference><Citation>Eagle Pharmaceuticals, I. (2018). RYANODEX (dantrolene sodium) for injectable suspension. For fast and efficient administration, choose Ryanodex
Retrieved
May 23, 2023
from https://www.ryanodex.com/why-ryanodex/</Citation></Reference><Reference><Citation>Ece B (2022). Nanofibers: Production, Characterization, and Tissue Engineering Applications. In Phuong VP (Ed.), 21st Century Nanostructured Materials (pp. Ch. 13). IntechOpen. 10.5772/intechopen.102787</Citation><ArticleIdList><ArticleId IdType="doi">10.5772/intechopen.102787</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency. ICH guideline S11 on nonclinical safety testing in support of development of paediatric pharmaceuticals. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guideline-s11-nonclinical-safety-testing-support-development-paediatric-pharmaceuticals-step-5_en.pdf</Citation></Reference><Reference><Citation>Feng Y, Chen X, Cassady K, Zou Z, Yang S, Wang Z, &amp; Zhang X (2020). The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside. Front Oncol, 10, 611690. 10.3389/fonc.2020.611690</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.611690</ArticleId><ArticleId IdType="pmc">PMC7821787</ArticleId><ArticleId IdType="pubmed">33489922</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming TR, Demets DL, &amp; McShane LM (2017). Discussion: The role, position, and function of the FDA-The past, present, and future. Biostatistics, 18(3), 417–421. 10.1093/biostatistics/kxx023</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biostatistics/kxx023</ArticleId><ArticleId IdType="pmc">PMC5862299</ArticleId><ArticleId IdType="pubmed">28633307</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung A, Yue X, Wigle PR, &amp; Guo JJ (2021). Off-label medication use in rare pediatric diseases in the United States. Intractable &amp; Rare Diseases Research, 10(4), 238–245. 10.5582/irdr.2021.01104</Citation><ArticleIdList><ArticleId IdType="doi">10.5582/irdr.2021.01104</ArticleId><ArticleId IdType="pmc">PMC8630459</ArticleId><ArticleId IdType="pubmed">34877235</ArticleId></ArticleIdList></Reference><Reference><Citation>Fütterer S, Andrusenko I, Kolb U, Hofmeister W, &amp; Langguth P (2013). Structural characterization of iron oxide/hydroxide nanoparticles in nine different parenteral drugs for the treatment of iron deficiency anaemia by electron diffraction (ED) and X-ray powder diffraction (XRPD). J Pharm Biomed Anal, 86, 151–160. 10.1016/j.jpba.2013.08.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpba.2013.08.005</ArticleId><ArticleId IdType="pubmed">23998966</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstick JE, Cunningham RM, &amp; Carter PM (2022). Current Causes of Death in Children and Adolescents in the United States. New england journal of medicine, 386(20), 1955–1956. 10.1056/NEJMc2201761</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2201761</ArticleId><ArticleId IdType="pmc">PMC10042524</ArticleId><ArticleId IdType="pubmed">35443104</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez MA, Ramírez Rigo MV, &amp; Gonzalez Vidal NL (2019). Orphan Formulations in Pediatric Schistosomiasis Treatment: Development and Characterization of Praziquantel Nanoparticle-Loaded Powders for Reconstitution. AAPS PharmSciTech, 20(8), 318. 10.1208/s12249-019-1548-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12249-019-1548-z</ArticleId><ArticleId IdType="pubmed">31620905</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenwood B (2014). The contribution of vaccination to global health: past, present and future. Philos Trans R Soc Lond B Biol Sci, 369(1645), 20130433. 10.1098/rstb.2013.0433</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.2013.0433</ArticleId><ArticleId IdType="pmc">PMC4024226</ArticleId><ArticleId IdType="pubmed">24821919</ArticleId></ArticleIdList></Reference><Reference><Citation>Groll AH, Rijnders BJA, Walsh TJ, Adler-Moore J, Lewis RE, &amp; Brüggemann RJM (2019). Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. Clin Infect Dis, 68(Suppl 4), S260–s274. 10.1093/cid/ciz076</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciz076</ArticleId><ArticleId IdType="pmc">PMC6495018</ArticleId><ArticleId IdType="pubmed">31222253</ArticleId></ArticleIdList></Reference><Reference><Citation>Guebre-Xabier M, Patel N, Tian JH, Zhou B, Maciejewski S, Lam K, Portnoff AD, Massare MJ, Frieman MB, Piedra PA, Ellingsworth L, Glenn G, &amp; Smith G (2020). NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine, 38(50), 7892–7896. 10.1016/j.vaccine.2020.10.064</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2020.10.064</ArticleId><ArticleId IdType="pmc">PMC7584426</ArticleId><ArticleId IdType="pubmed">33139139</ArticleId></ArticleIdList></Reference><Reference><Citation>Hack S, &amp; Chow B (2001). Pediatric psychotropic medication compliance: a literature review and research-based suggestions for improving treatment compliance. J Child Adolesc Psychopharmacol, 11(1), 59–67. 10.1089/104454601750143465</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/104454601750143465</ArticleId><ArticleId IdType="pubmed">11322747</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadj Hassine I (2022). Covid-19 vaccines and variants of concern: A review. Rev Med Virol, 32(4), e2313. 10.1002/rmv.2313</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2313</ArticleId><ArticleId IdType="pmc">PMC8646685</ArticleId><ArticleId IdType="pubmed">34755408</ArticleId></ArticleIdList></Reference><Reference><Citation>Hami Z (2021). A Brief Review on Advantages of Nano-based Drug Delivery Systems [Review Article]. Ann Mil Health Sci Res, 19(1), e112274. 10.5812/amh.112274</Citation><ArticleIdList><ArticleId IdType="doi">10.5812/amh.112274</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamill RJ (2013). Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs, 73(9), 919–934. 10.1007/s40265-013-0069-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-013-0069-4</ArticleId><ArticleId IdType="pubmed">23729001</ArticleId></ArticleIdList></Reference><Reference><Citation>Heo YA, Syed YY, &amp; Keam SJ (2019). Pegaspargase: A Review in Acute Lymphoblastic Leukaemia. Drugs, 79(7), 767–777. 10.1007/s40265-019-01120-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-019-01120-1</ArticleId><ArticleId IdType="pmc">PMC6531401</ArticleId><ArticleId IdType="pubmed">31030380</ArticleId></ArticleIdList></Reference><Reference><Citation>Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, &amp; Lyman GH (2017). Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol, 35(28), 3240–3261. 10.1200/jco.2017.74.4789</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2017.74.4789</ArticleId><ArticleId IdType="pubmed">28759346</ArticleId></ArticleIdList></Reference><Reference><Citation>Hills RA, &amp; Howarth M (2022). Virus-like particles against infectious disease and cancer: guidance for the nano-architect. Curr Opin Biotechnol, 73, 346–354. 10.1016/j.copbio.2021.09.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.copbio.2021.09.012</ArticleId><ArticleId IdType="pmc">PMC8555979</ArticleId><ArticleId IdType="pubmed">34735984</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotez PJ, &amp; Bottazzi ME (2022). Whole Inactivated Virus and Protein-Based COVID-19 Vaccines. Annu Rev Med, 73, 55–64. 10.1146/annurev-med-042420-113212</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-042420-113212</ArticleId><ArticleId IdType="pubmed">34637324</ArticleId></ArticleIdList></Reference><Reference><Citation>Houghton PJ, Kurmasheva RT (2019) Challenges and Opportunities for Childhood Cancer Drug Development. Pharmacol Rev, 71(4): 671–697. 10.1124/pr.118.016972</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.118.016972</ArticleId><ArticleId IdType="pmc">PMC6768308</ArticleId><ArticleId IdType="pubmed">31558580</ArticleId></ArticleIdList></Reference><Reference><Citation>Institute of Medicine. (2003). When children die: Improving palliative and end-of-life care for children and their families. (Field MJ &amp; Behrman RE, Eds.). National Acad. Press.</Citation><ArticleIdList><ArticleId IdType="pubmed">25057608</ArticleId></ArticleIdList></Reference><Reference><Citation>Irvine DJ, &amp; Dane EL (2020). Enhancing cancer immunotherapy with nanomedicine. Nat Rev Immunol, 20(5), 321–334. 10.1038/s41577-019-0269-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0269-6</ArticleId><ArticleId IdType="pmc">PMC7536618</ArticleId><ArticleId IdType="pubmed">32005979</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain K, Kesharwani P, Gupta U, &amp; Jain N (2010). Dendrimer Toxicity: Let’s Meet the Challenge. Int J Pharm, 394, 122–142. 10.1016/j.ijpharm.2010.04.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2010.04.027</ArticleId><ArticleId IdType="pubmed">20433913</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph PD, Craig JC, &amp; Caldwell PH (2015). Clinical trials in children. Br J Clin Pharmacol, 79(3), 357–369. 10.1111/bcp.12305</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.12305</ArticleId><ArticleId IdType="pmc">PMC4345947</ArticleId><ArticleId IdType="pubmed">24325152</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaurav M, Ruhi S, Al-Goshae HA, Jeppu AK, Ramachandran D, Sahu RK, Sarkar AK, Khan J, &amp; Ashif Ikbal AM (2023). Dendrimer: An update on recent developments and future opportunities for the brain tumors diagnosis and treatment [Review]. Frontiers in Pharmacology, 14. 10.3389/fphar.2023.1159131</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2023.1159131</ArticleId><ArticleId IdType="pmc">PMC10060650</ArticleId><ArticleId IdType="pubmed">37006997</ArticleId></ArticleIdList></Reference><Reference><Citation>Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, &amp; Kauffman RE (2003). Developmental Pharmacology — Drug Disposition, Action, and Therapy in Infants and Children. New england journal of medicine, 349(12), 1157–1167. 10.1056/NEJMra035092</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra035092</ArticleId><ArticleId IdType="pubmed">13679531</ArticleId></ArticleIdList></Reference><Reference><Citation>Keating GM (2009). Peginterferon-alpha-2a (40 kD): A review of its use in chronic hepatitis B. Drugs, 69(18), 2633–2660. 10.2165/11203660-000000000-00000</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11203660-000000000-00000</ArticleId><ArticleId IdType="pubmed">19943712</ArticleId></ArticleIdList></Reference><Reference><Citation>Keating GM, &amp; Noble S (2003). Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs, 63(10), 1021–1051. 10.2165/00003495-200363100-00006</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003495-200363100-00006</ArticleId><ArticleId IdType="pubmed">12699402</ArticleId></ArticleIdList></Reference><Reference><Citation>Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, Smith G, Patel N, Frieman MB, Haupt RE, Logue J, McGrath M, Weston S, Piedra PA, Desai C, Callahan K, Lewis M, Price-Abbott P, Formica N, Shinde V, Fries L, Lickliter JD, Griffin P, Wilkinson B, &amp; Glenn GM (2020). Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med, 383(24), 2320–2332. 10.1056/NEJMoa2026920</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2026920</ArticleId><ArticleId IdType="pmc">PMC7494251</ArticleId><ArticleId IdType="pubmed">32877576</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim NN, Parker RM, Weinbauer GF, Remick AK, &amp; Steinbach T (2017). Points to Consider in Designing and Conducting Juvenile Toxicology Studies. International journal of toxicology, 36(4), 325–339. 10.1177/1091581817699975</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1091581817699975</ArticleId><ArticleId IdType="pubmed">28466670</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Tewari M, Pajerowski JD, Cai S, Sen S, Williams J, Sirsi S, Lutz G, &amp; Discher DE (2009). Polymersome delivery of siRNA and antisense oligonucleotides. Journal of Controlled Release, 134(2), 132–140. 10.1016/j.jconrel.2008.10.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2008.10.020</ArticleId><ArticleId IdType="pmc">PMC2740336</ArticleId><ArticleId IdType="pubmed">19084037</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollmann TR, Levy O, Montgomery RR, &amp; Goriely S (2012). Innate immune function by Toll-like receptors: distinct responses in newborns and the elderly. Immunity, 37(5), 771–783. 10.1016/j.immuni.2012.10.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2012.10.014</ArticleId><ArticleId IdType="pmc">PMC3538030</ArticleId><ArticleId IdType="pubmed">23159225</ArticleId></ArticleIdList></Reference><Reference><Citation>Kon E, Elia U, &amp; Peer D (2022). Principles for designing an optimal mRNA lipid nanoparticle vaccine. Curr Opin Biotechnol, 73, 329–336. 10.1016/j.copbio.2021.09.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.copbio.2021.09.016</ArticleId><ArticleId IdType="pmc">PMC8547895</ArticleId><ArticleId IdType="pubmed">34715546</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, Stuart RK, Strickland SA, Hogge D, Solomon SR, Stone RM, Bixby DL, Kolitz JE, Schiller GJ, Wieduwilt MJ, Ryan DH, Hoering A, Banerjee K, Chiarella M, Louie AC, &amp; Medeiros BC (2018). CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol, 36(26), 2684–2692. 10.1200/jco.2017.77.6112</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.2017.77.6112</ArticleId><ArticleId IdType="pmc">PMC6127025</ArticleId><ArticleId IdType="pubmed">30024784</ArticleId></ArticleIdList></Reference><Reference><Citation>Laniado-Laborín R, &amp; Cabrales-Vargas MN (2009). Amphotericin B: side effects and toxicity. Rev Iberoam Micol, 26(4), 223–227. 10.1016/j.riam.2009.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.riam.2009.06.003</ArticleId><ArticleId IdType="pubmed">19836985</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, &amp; Wang Y (2022). Progress in the application of metagenomic next-generation sequencing in pediatric infectious diseases. Pediatr Neonatol, 63(5), 445–451. 10.1016/j.pedneo.2022.03.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pedneo.2022.03.014</ArticleId><ArticleId IdType="pubmed">35810069</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P, Chen G, &amp; Zhang J (2022). A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives. Molecules, 27(4). 10.3390/molecules27041372</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27041372</ArticleId><ArticleId IdType="pmc">PMC8879473</ArticleId><ArticleId IdType="pubmed">35209162</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H, &amp; Rosenbaum S (2014). Developmental pharmacokinetics in pediatric populations. J Pediatr Pharmacol Ther, 19(4), 262–276. 10.5863/1551-6776-19.4.262</Citation><ArticleIdList><ArticleId IdType="doi">10.5863/1551-6776-19.4.262</ArticleId><ArticleId IdType="pmc">PMC4341411</ArticleId><ArticleId IdType="pubmed">25762871</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu W, Yao J, Zhu X, &amp; Qi Y (2021). Nanomedicines: Redefining traditional medicine. Biomedicine &amp; Pharmacotherapy, 134, 111103. 10.1016/j.biopha.2020.111103</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.111103</ArticleId><ArticleId IdType="pubmed">33338747</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyseng-Williamson KA, &amp; Keating GM (2009). Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs, 69(6), 739–756. 10.2165/00003495-200969060-00007</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003495-200969060-00007</ArticleId><ArticleId IdType="pubmed">19405553</ArticleId></ArticleIdList></Reference><Reference><Citation>Madkhali OA (2022). Perspectives and Prospective on Solid Lipid Nanoparticles as Drug Delivery Systems. Molecules, 27(5). 10.3390/molecules27051543</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules27051543</ArticleId><ArticleId IdType="pmc">PMC8911793</ArticleId><ArticleId IdType="pubmed">35268643</ArticleId></ArticleIdList></Reference><Reference><Citation>Marenco M, Canziani L, De Matteis G, Cavenaghi G, Aprile C, &amp; Lodola L (2021). Chemical and Physical Characterisation of Human Serum Albumin Nanocolloids: Kinetics, Strength and Specificity of Bonds with 99mTc and 68Ga. Nanomaterials, 11(7), 1776. https://www.mdpi.com/2079-4991/11/7/1776
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8308145</ArticleId><ArticleId IdType="pubmed">34361162</ArticleId></ArticleIdList></Reference><Reference><Citation>Medvedeva AA, Sinilkin IG, Zelchan RV, Chernov VI, Lyapunov AY, Bragina OD, Varlamova N, Skuridin V, &amp; Dergilev AP (2016). The Study of 99m Tc-Aluminum Oxide Using for Sentinel Lymph Nodes Detection in Experiment. IOP Conference Series: Materials Science and Engineering, 135, 012027. 10.1088/1757-899X/135/1/012027</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/1757-899X/135/1/012027</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta AM, Sonabend AM, &amp; Bruce JN (2017). Convection-Enhanced Delivery. Neurotherapeutics, 14(2), 358–371. 10.1007/s13311-017-0520-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-017-0520-4</ArticleId><ArticleId IdType="pmc">PMC5398992</ArticleId><ArticleId IdType="pubmed">28299724</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, &amp; Langer R (2021). Engineering precision nanoparticles for drug delivery. Nature Reviews Drug Discovery, 20(2), 101–124. 10.1038/s41573-020-0090-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-020-0090-8</ArticleId><ArticleId IdType="pmc">PMC7717100</ArticleId><ArticleId IdType="pubmed">33277608</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammed NI, Wason J, Mendy T, Nass SA, Ofordile O, Camara F, Baldeh B, Sanyang C, Jallow AT, Hossain I, Faria N, Powell JJ, Prentice AM, &amp; Pereira DIA (2023). A novel nano-iron supplement versus standard treatment for iron deficiency anaemia in children 6–35 months (IHAT-GUT trial): a double-blind, randomised, placebo-controlled non-inferiority phase II trial in The Gambia. eClinicalMedicine, 56, 101853. 10.1016/j.eclinm.2023.101853</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.101853</ArticleId><ArticleId IdType="pmc">PMC9985047</ArticleId><ArticleId IdType="pubmed">36880049</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohsen MO, Speiser DE, Knuth A, &amp; Bachmann MF (2020). Virus-like particles for vaccination against cancer. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 12(1), e1579. 10.1002/wnan.1579</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wnan.1579</ArticleId><ArticleId IdType="pmc">PMC6916610</ArticleId><ArticleId IdType="pubmed">31456339</ArticleId></ArticleIdList></Reference><Reference><Citation>Muir LA, Nguyen QG, Hauschka SD, &amp; Chamberlain JS (2014). Engraftment potential of dermal fibroblasts following in vivo myogenic conversion in immunocompetent dystrophic skeletal muscle. Molecular Therapy - Methods &amp; Clinical Development, 1, 14025. 10.1038/mtm.2014.25</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mtm.2014.25</ArticleId><ArticleId IdType="pmc">PMC4280788</ArticleId><ArticleId IdType="pubmed">25558461</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullard A (2023). 2022 FDA approvals. Nat Rev Drug Discov, 22(2), 83–88. 10.1038/d41573-023-00001-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41573-023-00001-3</ArticleId><ArticleId IdType="pubmed">36596858</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Tompkins KR, Walsh EE, Frenck R, Falsey AR, Dormitzer PR, Gruber WC, Şahin U, &amp; Jansen KU (2020). Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature, 586(7830), 589–593. 10.1038/s41586-020-2639-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2639-4</ArticleId><ArticleId IdType="pubmed">32785213</ArticleId></ArticleIdList></Reference><Reference><Citation>Naert T, Colpaert R, Van Nieuwenhuysen T, Dimitrakopoulou D, Leoen J, Haustraete J, Boel A, Steyaert W, Lepez T, Deforce D, Willaert A, Creytens D, &amp; Vleminckx K (2016). CRISPR/Cas9 mediated knockout of rb1 and rbl1 leads to rapid and penetrant retinoblastoma development in Xenopus tropicalis. Sci Rep, 6, 35264. 10.1038/srep35264</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep35264</ArticleId><ArticleId IdType="pmc">PMC5064383</ArticleId><ArticleId IdType="pubmed">27739525</ArticleId></ArticleIdList></Reference><Reference><Citation>Nance ME, Hakim CH, Yang NN, &amp; Duan D (2018). Nanotherapy for Duchenne muscular dystrophy. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 10(2). 10.1002/wnan.1472</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wnan.1472</ArticleId><ArticleId IdType="pmc">PMC5636659</ArticleId><ArticleId IdType="pubmed">28398005</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardin A, L. L. M, Labroquere K, Faure O and Abastado PJ (2006). Liposomal Muramyl Tripeptide Phosphatidylethanolamine: Targeting and Activating Macrophages for Adjuvant Treatment of Osteosarcoma. Current Cancer Drug Targets.</Citation><ArticleIdList><ArticleId IdType="pubmed">16529542</ArticleId></ArticleIdList></Reference><Reference><Citation>Nayl AA, Abd-Elhamid AI, Awwad NS, Abdelgawad MA, Wu J, Mo X, Gomha SM, Aly AA, &amp; Bräse S (2022). Recent Progress and Potential Biomedical Applications of Electrospun Nanofibers in Regeneration of Tissues and Organs. Polymers (Basel), 14(8). 10.3390/polym14081508</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/polym14081508</ArticleId><ArticleId IdType="pmc">PMC9029721</ArticleId><ArticleId IdType="pubmed">35458258</ArticleId></ArticleIdList></Reference><Reference><Citation>Nederlof A, Kitchen S, Meijer P, Cnossen M, Ali Pour N, Kershaw G, Jennings I, Walker I, &amp; de Maat MPM (2020). Performance of factor IX extended half-life product measurements in external quality control assessment programs. J Thromb Haemost, 18(8), 1874–1883. 10.1111/jth.14847</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14847</ArticleId><ArticleId IdType="pmc">PMC7496271</ArticleId><ArticleId IdType="pubmed">32311825</ArticleId></ArticleIdList></Reference><Reference><Citation>Negishi Y, Ishii Y, Shiono H, Akiyama S, Sekine S, Kojima T, Mayama S, Kikuchi T, Hamano N, Endo-Takahashi Y, Suzuki R, Maruyama K, &amp; Aramaki Y (2014). Bubble liposomes and ultrasound exposure improve localized morpholino oligomer delivery into the skeletal muscles of dystrophic mdx mice. Mol Pharm, 11(3), 1053–1061. 10.1021/mp4004755</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/mp4004755</ArticleId><ArticleId IdType="pubmed">24433046</ArticleId></ArticleIdList></Reference><Reference><Citation>Olin A, Henckel E, Chen Y, Lakshmikanth T, Pou C, Mikes J, Gustafsson A, Bernhardsson AK, Zhang C, Bohlin K, &amp; Brodin P (2018). Stereotypic Immune System Development in Newborn Children. Cell, 174(5), 1277–1292.e1214. 10.1016/j.cell.2018.06.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.06.045</ArticleId><ArticleId IdType="pmc">PMC6108833</ArticleId><ArticleId IdType="pubmed">30142345</ArticleId></ArticleIdList></Reference><Reference><Citation>Omidian H, &amp; Mfoafo K (2023). Exploring the Potential of Nanotechnology in Pediatric Healthcare: Advances, Challenges, and Future Directions. Pharmaceutics, 15(6), 1583. 10.3390/pharmaceutics15061583</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics15061583</ArticleId><ArticleId IdType="pmc">PMC10303369</ArticleId><ArticleId IdType="pubmed">37376032</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardridge WM (2005). The blood-brain barrier: bottleneck in brain drug development. NeuroRx, 2(1), 3–14. 10.1602/neurorx.2.1.3</Citation><ArticleIdList><ArticleId IdType="doi">10.1602/neurorx.2.1.3</ArticleId><ArticleId IdType="pmc">PMC539316</ArticleId><ArticleId IdType="pubmed">15717053</ArticleId></ArticleIdList></Reference><Reference><Citation>Parums DV (2022). Editorial: First Approval of the Protein-Based Adjuvanted Nuvaxovid (NVX-CoV2373) Novavax Vaccine for SARS-CoV-2 Could Increase Vaccine Uptake and Provide Immune Protection from Viral Variants. Med Sci Monit, 28, e936523. 10.12659/msm.936523</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/msm.936523</ArticleId><ArticleId IdType="pmc">PMC8897963</ArticleId><ArticleId IdType="pubmed">35228506</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel R, Kaki M, Potluri VS, Kahar P, &amp; Khanna D (2022). A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna &amp; Johnson &amp; Johnson. Hum Vaccin Immunother, 18(1), 2002083. 10.1080/21645515.2021.2002083</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2021.2002083</ArticleId><ArticleId IdType="pmc">PMC8862159</ArticleId><ArticleId IdType="pubmed">35130825</ArticleId></ArticleIdList></Reference><Reference><Citation>Peginterferon Alfa. (2006). In Drugs and Lactation Database (LactMed®). National Institute of Child Health and Human Development.</Citation><ArticleIdList><ArticleId IdType="pubmed">29999705</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira DIA, Mohammed NI, Ofordile O, Camara F, Baldeh B, Mendy T, Sanyang C, Jallow AT, Hossain I, Wason J, &amp; Prentice AM (2018). A novel nano-iron supplement to safely combat iron deficiency and anaemia in young children: The IHAT-GUT double-blind, randomised, placebo-controlled trial protocol. Gates Open Res, 2, 48. 10.12688/gatesopenres.12866.2</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/gatesopenres.12866.2</ArticleId><ArticleId IdType="pmc">PMC6266659</ArticleId><ArticleId IdType="pubmed">30569038</ArticleId></ArticleIdList></Reference><Reference><Citation>Pestka S (2007). The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem, 282(28), 20047–20051. 10.1074/jbc.R700004200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.R700004200</ArticleId><ArticleId IdType="pubmed">17502369</ArticleId></ArticleIdList></Reference><Reference><Citation>Piedmonte DM, &amp; Treuheit MJ (2008). Formulation of Neulasta (pegfilgrastim). Adv Drug Deliv Rev, 60(1), 50–58. 10.1016/j.addr.2007.04.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2007.04.017</ArticleId><ArticleId IdType="pubmed">17822802</ArticleId></ArticleIdList></Reference><Reference><Citation>Pingale P, Kendre P, Pardeshi K, &amp; Rajput A (2023). An emerging era in manufacturing of drug delivery systems: Nanofabrication techniques. Heliyon, 9(3), e14247. 10.1016/j.heliyon.2023.e14247</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e14247</ArticleId><ArticleId IdType="pmc">PMC10018573</ArticleId><ArticleId IdType="pubmed">36938476</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard AJ, &amp; Bijker EM (2021). A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol, 21(2), 83–100. 10.1038/s41577-020-00479-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-00479-7</ArticleId><ArticleId IdType="pmc">PMC7754704</ArticleId><ArticleId IdType="pubmed">33353987</ArticleId></ArticleIdList></Reference><Reference><Citation>Qianqian Liu Y-JK, Gwang-Bum Im, Jintao Zhu, Yuzhou Wu, Yijing Liu, Suk Ho Bhang. (2020). Inorganic Nanoparticles Applied as Functional Therapeutics. Wiley Online Library, 31(12). 10.1002/adfm.202008171</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adfm.202008171</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratto D, &amp; Joyner RW (2023). Dantrolene. In StatPearls. StatPearls Publishing</Citation><ArticleIdList><ArticleId IdType="pubmed">30571019</ArticleId></ArticleIdList></Reference><Reference><Citation>Copyright © 2023, StatPearls Publishing LLC.</Citation></Reference><Reference><Citation>Reber A, &amp; Katz J (2013). Immunological assessment of influenza vaccines and immune correlates of protection. Expert Rev Vaccines, 12(5), 519–536. 10.1586/erv.13.35</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.13.35</ArticleId><ArticleId IdType="pmc">PMC9002926</ArticleId><ArticleId IdType="pubmed">23659300</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimessi P, Sabatelli P, Fabris M, Braghetta P, Bassi E, Spitali P, Vattemi G, Tomelleri G, Mari L, Perrone D, Medici A, Neri M, Bovolenta M, Martoni E, Maraldi NM, Gualandi F, Merlini L, Ballestri M, Tondelli L, Sparnacci K, Bonaldo P, Caputo A, Laus M, &amp; Ferlini A (2009). Cationic PMMA nanoparticles bind and deliver antisense oligoribonucleotides allowing restoration of dystrophin expression in the mdx mouse. Mol Ther, 17(5), 820–827. 10.1038/mt.2009.8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2009.8</ArticleId><ArticleId IdType="pmc">PMC2835127</ArticleId><ArticleId IdType="pubmed">19240694</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodríguez F, Caruana P, De la Fuente N, Español P, Gámez M, Balart J, Llurba E, Rovira R, Ruiz R, Martín-Lorente C, Corchero JL, &amp; Céspedes MV (2022). Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges. Biomolecules, 12(6). 10.3390/biom12060784</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom12060784</ArticleId><ArticleId IdType="pmc">PMC9221343</ArticleId><ArticleId IdType="pubmed">35740909</ArticleId></ArticleIdList></Reference><Reference><Citation>Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, &amp; Warr D (2010). Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol, 21 Suppl 5, v232–243. 10.1093/annonc/mdq194</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdq194</ArticleId><ArticleId IdType="pubmed">20555089</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose K, &amp; Anker J. v. d. (2011). Guide to Paediatric Drug Development and Clinical Research. In Br J Clin Pharmacol (Vol. 71, pp. 142). Copyright © 2011 The British Pharmacological Society. 10.1111/j.1365-2125.2010.03796.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.2010.03796.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg H, Pollock N, Schiemann A, Bulger T, &amp; Stowell K (2015). Malignant hyperthermia: a review. Orphanet J Rare Dis, 10, 93. 10.1186/s13023-015-0310-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-015-0310-1</ArticleId><ArticleId IdType="pmc">PMC4524368</ArticleId><ArticleId IdType="pubmed">26238698</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg H, Sambuughin N, Riazi S, &amp; Dirksen R (1993). Malignant Hyperthermia Susceptibility. In Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, &amp; Amemiya A (Eds.), GeneReviews(®). University of Washington, Seattle</Citation><ArticleIdList><ArticleId IdType="pubmed">20301325</ArticleId></ArticleIdList></Reference><Reference><Citation>Copyright © 1993–2023, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</Citation></Reference><Reference><Citation>Rosenblum D, Gutkin A, Kedmi R, Ramishetti S, Veiga N, Jacobi AM, Schubert MS, Friedmann-Morvinski D, Cohen ZR, Behlke MA, Lieberman J, &amp; Peer D (2020). CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci Adv, 6(47). 10.1126/sciadv.abc9450</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abc9450</ArticleId><ArticleId IdType="pmc">PMC7673804</ArticleId><ArticleId IdType="pubmed">33208369</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampath V, Rabinowitz G, Shah M, Jain S, Diamant Z, Jesenak M, Rabin R, Vieths S, Agache I, Akdis M, Barber D, Breiteneder H, Chinthrajah S, Chivato T, Collins W, Eiwegger T, Fast K, Fokkens W, O’Hehir RE, Ollert M, O’Mahony L, Palomares O, Pfaar O, Riggioni C, Shamji MH, Sokolowska M, Jose Torres M, Traidl-Hoffmann C, van Zelm M, Wang Y, Zhang L, Akdis CA, &amp; Nadeau KC (2021). Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives. Allergy, 76(6), 1640–1660. 10.1111/all.14840</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14840</ArticleId><ArticleId IdType="pmc">PMC8251022</ArticleId><ArticleId IdType="pubmed">33811364</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardesai S, Biniwale M, Wertheimer F, Garingo A, &amp; Ramanathan R (2017). Evolution of surfactant therapy for respiratory distress syndrome: past, present, and future. Pediatr Res, 81(1–2), 240–248. 10.1038/pr.2016.203</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/pr.2016.203</ArticleId><ArticleId IdType="pubmed">27706130</ArticleId></ArticleIdList></Reference><Reference><Citation>Saso A, &amp; Kampmann B (2017). Vaccine responses in newborns. Semin Immunopathol, 39(6), 627–642. 10.1007/s00281-017-0654-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-017-0654-9</ArticleId><ArticleId IdType="pmc">PMC5711983</ArticleId><ArticleId IdType="pubmed">29124321</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvakumar SC, Preethi KA, Ross K, Tusubira D, Khan MWA, Mani P, Rao TN, &amp; Sekar D (2022). CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer. Mol Cancer, 21(1), 83. 10.1186/s12943-022-01565-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-022-01565-1</ArticleId><ArticleId IdType="pmc">PMC8944095</ArticleId><ArticleId IdType="pubmed">35331236</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, Mohammadi P, Nomovi M, &amp; Mowla A (2021). Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. J Neurol Sci, 428, 117607. 10.1016/j.jns.2021.117607</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.117607</ArticleId><ArticleId IdType="pmc">PMC8330139</ArticleId><ArticleId IdType="pubmed">34365148</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng Y, Hu J, Shi J, &amp; Lee LJ (2019). Stimuli-responsive Carriers for Controlled Intracellular Drug Release. Curr Med Chem, 26(13), 2377–2388. 10.2174/0929867324666170830102409</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867324666170830102409</ArticleId><ArticleId IdType="pubmed">28875840</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim S, &amp; Wong NK (2021). Nanotechnology and its use in imaging and drug delivery (Review). Biomed Rep, 14(5), 42. 10.3892/br.2021.1418</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/br.2021.1418</ArticleId><ArticleId IdType="pmc">PMC7953199</ArticleId><ArticleId IdType="pubmed">33728048</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon AK, Hollander GA, &amp; McMichael A (2015). Evolution of the immune system in humans from infancy to old age. Proc Biol Sci, 282(1821), 20143085. 10.1098/rspb.2014.3085</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rspb.2014.3085</ArticleId><ArticleId IdType="pmc">PMC4707740</ArticleId><ArticleId IdType="pubmed">26702035</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh B, Yang S, Krishna A, &amp; Sridhar S (2020). Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy. Frontiers in chemistry, 8, 594619–594619. 10.3389/fchem.2020.594619</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fchem.2020.594619</ArticleId><ArticleId IdType="pmc">PMC7719718</ArticleId><ArticleId IdType="pubmed">33330383</ArticleId></ArticleIdList></Reference><Reference><Citation>Sosnik A, &amp; Carcaboso AM (2014). Nanomedicines in the future of pediatric therapy. Adv Drug Deliv Rev, 73, 140–161. 10.1016/j.addr.2014.05.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2014.05.004</ArticleId><ArticleId IdType="pubmed">24819219</ArticleId></ArticleIdList></Reference><Reference><Citation>Spadoni C (2019). Pediatric Drug Development: Challenges and Opportunities. Curr Ther Res Clin Exp, 90, 119–122. 10.1016/j.curtheres.2018.12.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.curtheres.2018.12.001</ArticleId><ArticleId IdType="pmc">PMC6677569</ArticleId><ArticleId IdType="pubmed">31388366</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein MA, Weiss M, &amp; Hlavaty L (2012). ADHD treatments, sleep, and sleep problems: complex associations. Neurotherapeutics, 9(3), 509–517. 10.1007/s13311-012-0130-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-012-0130-0</ArticleId><ArticleId IdType="pmc">PMC3441938</ArticleId><ArticleId IdType="pubmed">22718078</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian JH, Patel N, Haupt R, Zhou H, Weston S, Hammond H, Logue J, Portnoff AD, Norton J, Guebre-Xabier M, Zhou B, Jacobson K, Maciejewski S, Khatoon R, Wisniewska M, Moffitt W, Kluepfel-Stahl S, Ekechukwu B, Papin J, Boddapati S, Jason Wong C, Piedra PA, Frieman MB, Massare MJ, Fries L, Bengtsson KL, Stertman L, Ellingsworth L, Glenn G, &amp; Smith G (2021). SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun, 12(1), 372. 10.1038/s41467-020-20653-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20653-8</ArticleId><ArticleId IdType="pmc">PMC7809486</ArticleId><ArticleId IdType="pubmed">33446655</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolmar I (2020). Fensolvi® (leuprolide acetate) - FDA-Approved Treatment. Retrieved
May 23, 2023
from https://fensolvi.com/</Citation></Reference><Reference><Citation>Tzogani K, Penttilä K, Lapveteläinen T, Hemmings R, Koenig J, Freire J, Márcia S, Cole S, Coppola P, Flores B, Barbachano Y, Roige SD, &amp; Pignatti F (2020). EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes. Oncologist, 25(9), e1414–e1420. 10.1634/theoncologist.2019-0785</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.2019-0785</ArticleId><ArticleId IdType="pmc">PMC7485353</ArticleId><ArticleId IdType="pubmed">32282100</ArticleId></ArticleIdList></Reference><Reference><Citation>Underwood E, Dunkle LM, Madhi SA, Gay CL, Heath PT, Kotloff KL, Smith K, Chau G, Galbiati S, McGarry A, Woo W, Cho I, Alves K, Áñez G, Bennett C, Shinde V, Fries L, Mallory RM, Glenn GM, &amp; Toback S (2023). Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine. Expert Rev Vaccines, 22(1), 501–517. 10.1080/14760584.2023.2218913</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2023.2218913</ArticleId><ArticleId IdType="pubmed">37246757</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration. (a). Coronavirus (COVID-19) update: FDA authorizes Moderna and Pfizer-BioNTech covid-19 vaccines for children down to 6 months of age
FDA.gov.
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-covid-19-vaccines-children</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration. (b). Moderna Covid-19 vaccine fact sheet for recipients and caregivers. FDA.gov.
https://www.fda.gov/media/144638/download?mc_cid=5e608fee98&amp;mc_eid=f57cc819b5</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration. (c). Nonclinical Safety Evaluation of Pediatric Drug Products. FDA.gov.
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-safety-evaluation-pediatric-drug-products</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration. (d). Pfizer-BioNTech COVID-19 Vaccine. FDA.gov.
https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-regulated-biologics/pfizer-biontech-covid-19-vaccine</Citation></Reference><Reference><Citation>U.S. Food and Drug Administration. (e). The FDA’s Drug Review process: Ensuring drugs are safe and effective. FDA.gov.
https://www.fda.gov/drugs/information-consumers-and-patients-drugs/fdas-drug-review-process-ensuring-drugs-are-safe-and-effective</Citation></Reference><Reference><Citation>U.S. National Library of Medicine. (a). CED of MTX110 newly diagnosed diffuse midline gliomas. ClinicalTrials.gov.
https://classic.clinicaltrials.gov/ct2/show/NCT04264143</Citation></Reference><Reference><Citation>U.S. National Library of Medicine. (b). Clinical assessment of voriconazole self nano emulsifying drug delivery system intermediate gel. ClinicalTrials.gov.
https://classic.clinicaltrials.gov/ct2/show/NCT04110860</Citation></Reference><Reference><Citation>U.S. National Library of Medicine. (c). Imaging kidney transplant rejection using Ferumoxytol-enhanced magnetic resonance. ClinicalTrials.gov.
https://classic.clinicaltrials.gov/ct2/show/NCT02006108</Citation></Reference><Reference><Citation>U.S. National Library of Medicine. (d). Nanoparticle albumin-bound rapamycin, temozolomide, and irinotecan hydrochloride in treating pediatric patients with recurrent or refractory solid tumors - full text view. ClinicalTrials.gov.
https://classic.clinicaltrials.gov/ct2/show/NCT02975882</Citation></Reference><Reference><Citation>U.S. National Library of Medicine. (e). Phase 2 basket trial of NAB-sirolimus in patients with malignant solid tumors with pathogenic alterations in TSC1/TSC2 genes (precision 1). ClinicalTrials.gov.
https://www.clinicaltrials.gov/ct2/show/NCT05103358</Citation></Reference><Reference><Citation>U.S. National Library of Medicine. (f). Rectal dexmedetomidine niosomes for postoperative analgesia in pediatric cancer patients. ClinicalTrials.gov.
https://classic.clinicaltrials.gov/ct2/show/NCT05340725</Citation></Reference><Reference><Citation>Ventola CL (2017). Progress in Nanomedicine: Approved and Investigational Nanodrugs. P t, 42(12), 742–755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5720487</ArticleId><ArticleId IdType="pubmed">29234213</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner AJ, Ravi V, Riedel RF, Ganjoo K, Van Tine BA, Chugh R, Cranmer L, Gordon EM, Hornick JL, Du H, Grigorian B, Schmid AN, Hou S, Harris K, Kwiatkowski DJ, Desai NP, &amp; Dickson MA (2021). nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. J Clin Oncol, 39(33), 3660–3670. 10.1200/jco.21.01728</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/jco.21.01728</ArticleId><ArticleId IdType="pmc">PMC8601264</ArticleId><ArticleId IdType="pubmed">34637337</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen R, Umeano AC, Kou Y, Xu J, &amp; Farooqi AA (2019). Nanoparticle systems for cancer vaccine. Nanomedicine (Lond), 14(5), 627–648. 10.2217/nnm-2018-0147</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nnm-2018-0147</ArticleId><ArticleId IdType="pmc">PMC6439506</ArticleId><ArticleId IdType="pubmed">30806568</ArticleId></ArticleIdList></Reference><Reference><Citation>Winnick S, Lucas DO, Hartman AL, &amp; Toll D (2005). How do you improve compliance? Pediatrics, 115(6), e718–724. 10.1542/peds.2004-1133</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2004-1133</ArticleId><ArticleId IdType="pubmed">15930200</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright KD, Power HA, &amp; Shivak SM (2022). Child Health and Illness. Comprehensive Clinical Psychology, 501–513. 10.1016/b978-0-12-818697-8.00145-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/b978-0-12-818697-8.00145-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia S, Duan K, Zhang Y, Zeng X, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Li Q, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Nian X, Deng T, Yuan Z, Shen S, Guo W, Liu J, &amp; Yang X (2022). Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial [Clinical Trial]. Frontiers in Immunology, 13. 10.3389/fimmu.2022.898151</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.898151</ArticleId><ArticleId IdType="pmc">PMC9265248</ArticleId><ArticleId IdType="pubmed">35812412</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, &amp; Yang X (2020). Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. Jama, 324(10), 951–960. 10.1001/jama.2020.15543</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.15543</ArticleId><ArticleId IdType="pmc">PMC7426884</ArticleId><ArticleId IdType="pubmed">32789505</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia X (2021). Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design. Viruses, 13(1). 10.3390/v13010109</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13010109</ArticleId><ArticleId IdType="pmc">PMC7829931</ArticleId><ArticleId IdType="pubmed">33466921</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M, Wei S, Duan L, Ji Y, Han X, Sun Q, &amp; Weng L (2024). The recent advancements in protein nanoparticles for immunotherapy. Nanoscale, 16, 11825–11848. 10.1039/d4nr00537f</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/d4nr00537f</ArticleId><ArticleId IdType="pubmed">38814163</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X, Liu C, Wang Y, Koivisto O, Zhou J, Shu Y, &amp; Zhang H (2021). Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment. Adv Drug Deliv Rev, 176, 113891. 10.1016/j.addr.2021.113891</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2021.113891</ArticleId><ArticleId IdType="pubmed">34324887</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Green A, Brown N, Robinson A, Senat M, Testino B, Dinulescu DM, &amp; Sridhar S (2023). Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer. Front Oncol, 13, 1175617. 10.3389/fonc.2023.1175617</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2023.1175617</ArticleId><ArticleId IdType="pmc">PMC10203577</ArticleId><ArticleId IdType="pubmed">37228496</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S, Wallach M, Krishna A, Kurmasheva R, &amp; Sridhar S (2021). Recent Developments in Nanomedicine for Pediatric Cancer. Journal of clinical medicine, 10(7). 10.3390/jcm10071437</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10071437</ArticleId><ArticleId IdType="pmc">PMC8036287</ArticleId><ArticleId IdType="pubmed">33916177</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, Wu S, Deng Y, Zhang J, &amp; Shao A (2020). Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance [Review]. Frontiers in Molecular Biosciences, 7. 10.3389/fmolb.2020.00193</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2020.00193</ArticleId><ArticleId IdType="pmc">PMC7468194</ArticleId><ArticleId IdType="pubmed">32974385</ArticleId></ArticleIdList></Reference><Reference><Citation>Yellepeddi VK, Joseph A, &amp; Nance E (2019). Pharmacokinetics of nanotechnology-based formulations in pediatric populations. Adv Drug Deliv Rev, 151–152, 44–55. 10.1016/j.addr.2019.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2019.08.008</ArticleId><ArticleId IdType="pmc">PMC6893132</ArticleId><ArticleId IdType="pubmed">31494124</ArticleId></ArticleIdList></Reference><Reference><Citation>Yohan A, Jacques C, Fletcher T, Suk-In T, Campbell RB. (2022). An Overview of Conventional Drugs and Nanotherapeutic Options for the Treatment and Management of Pediatric Acute Lymphoblastic Leukemia. Anticancer Agents Med Chem. 2022;22(18):3050–3061. 10.2174/1871520622666220426105922</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871520622666220426105922</ArticleId><ArticleId IdType="pubmed">35473534</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeuzem S (2008). Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat Clin Pract Gastroenterol Hepatol, 5(11), 610–622. 10.1038/ncpgasthep1274</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncpgasthep1274</ArticleId><ArticleId IdType="pubmed">18838975</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D, Baldwin P, Leal AS, Carapellucci S, Sridhar S, &amp; Liby KT (2019). A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice. Theranostics, 9(21), 6224–6238. 10.7150/thno.36281</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.36281</ArticleId><ArticleId IdType="pmc">PMC6735511</ArticleId><ArticleId IdType="pubmed">31534547</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C, &amp; Middelberg AP (2014). Nanoparticle vaccines. Vaccine, 32(3), 327–337. 10.1016/j.vaccine.2013.11.069</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.11.069</ArticleId><ArticleId IdType="pubmed">24295808</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>